{
  "attach_pages": "17",
  "attach_size": "721",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201705150581256592_1.pdf?1494865418000.pdf",
  "company_code": "80000033",
  "eitime": "2017-05-15 16:24:08",
  "extend": {},
  "info_code": "AP201705150581256592",
  "language": "0",
  "notice_date": "2017-05-15 00:00:00",
  "notice_title": "从药品CRO向医疗器械延伸，BE业务带来业绩增量",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "publish_relation": {
    "originalCode": "465",
    "publishName": "化学制药"
  },
  "rating": "BBB",
  "researcher": "黄文忠,周豫",
  "security": [
    {
      "market_uni": "0",
      "publish_relation": [
        {
          "originalCode": "727",
          "publishName": "医疗服务"
        }
      ],
      "short_name": "泰格医药",
      "short_name_ch": "泰格医药",
      "short_name_cht": "泰格醫藥",
      "short_name_en": "TIGERMED",
      "stock": "300347"
    }
  ],
  "short_name": "泰格医药",
  "source_sample_name": "长城国瑞证券",
  "star": "2"
}